Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

VRDN

Viridian Therapeutics, Inc.\DE

Pharmaceutical Preparations · SIC 2834CIK 1590750Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$71.0M
Net Income FY2025
$(343.0M)
EPS (Basic, as reported)
—
Net Margin FY2025
-483.6%
ROE FY2025
-47.4%
Total Equity
$722.0M
Shares Out
113M
Business description

Viridian Therapeutics, Inc.\DE — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2013–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 3 → 71 +42.1% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020⚑FY2021⚑FY2022⚑FY2023FY2024FY2025
Revenue34841320071
Cost of revenue(3)—————————
Research & development(1)(20)(30)(35)——————
Selling, general & administrative———————(95)(61)(95)
Selling & marketing(2)—————————
General & administrative(8)(11)(11)(12)(13)(26)(35)(95)(61)—
Total operating expenses(20)(31)(41)(46)(111)(83)(136)(255)(299)(434)
Operating income(13)(27)(33)(42)(110)(80)(134)(254)(299)(363)
Interest expense00(1)(1)(1)00(2)(3)(5)
Interest & investment income———————183227
Other income (expense), net0011004172921
Income tax expense—————————0
Net income(13)(27)(33)(42)(111)(79)(130)(238)(270)(343)
EPS — basic————($31.13)($6.66)($4.05)($5.31)——
EPS — diluted————($31.13)($6.66)($4.05)($5.31)——
Shares outstanding — basic (M)————4123245——
Shares outstanding — diluted (M)————4123245——

Showing the latest 10 of 13 fiscal years.

  • ⚑ Weighted-average shares changed ×3.00 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×2.67 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×1.41 between FY2022 and FY2023 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.